Key result
Uninterrupted anticoagulation resolves recurrent bioprosthetic mitral valve thrombosis within 3 months.
Why the study?
Bioprosthetic valve thrombosis is more common than previously thought and likely underreported, with potential for accurate diagnosis and successful treatment with anticoagulation.
Case Report (n=1)
May support anticoagulation for recurrent bioprosthetic mitral valve thrombosis in select cases; leaves open need for prospective trials on duration and selection.
Bioprosthetic valve thrombosis (BPVT) is more common than previously thought and likely underreported. BPVT can be accurately diagnosed with cardiac imaging and treated successfully with anticoagulation, thus preventing reoperation. We hereby report a case of recurrent BPVT in the mitral position successfully treated with anticoagulation along with review of literature.
No takes yet. Share an insight, caveat, or question.
Fernandes et al. (2020) conducted a case report in Recurrent bioprosthetic mitral valve thrombosis (n=1). Anticoagulation (Unfractionated heparin and warfarin) was evaluated on Resolution of bioprosthetic valve thrombosis and reduction of transvalvular gradient. Three months of uninterrupted anticoagulation successfully resolved recurrent bioprosthetic mitral valve thrombosis, completely eliminating valve thickening and reducing the mean transvalvular gradient.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: